Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ: NMRA )

9.680 -0.160 (-1.63%)
Streaming Delayed Price Updated: 11:06 AM EST, Nov 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 275,357
Open 9.690
Bid (Size) 9.670 (4)
Ask (Size) 9.700 (5)
Prev. Close 9.840
Today's Range 9.340 - 9.850
52wk Range 8.330 - 21.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
Via Benzinga

Performance

YTD
-42.72%
-42.72%
1 Month
-31.10%
-31.10%
3 Month
-18.31%
-18.31%
6 Month
-0.10%
-0.10%
1 Year
-18.31%
-18.31%

More News

Read More
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Neumora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
From Neumora Therapeutics, Inc.
Via GlobeNewswire
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024
Via InvestorPlace
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
From Neumora Therapeutics, Inc.
Via GlobeNewswire
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024
Via InvestorPlace
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics to Participate in Upcoming Conferences in May
From Neumora Therapeutics, Inc.
Via GlobeNewswire
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?
Via Benzinga
Exposures Product Safety
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
Via Investor's Business Daily
Why Is Mobile Global Esports (MGAM) Stock Down 18% Today?
Via InvestorPlace
Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today?
Via InvestorPlace
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.